Evaluation Liverghol Impact on Liver Enzymes
Phase 3
- Conditions
- Thalassemia Major and Intermedia.Thalassemia
- Registration Number
- IRCT20150119020715N9
- Lead Sponsor
- Arak University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Patients over 5 years of age with ß-thalassemia Major and Intermedia referring to Amir Kabir hospital in Arak
Informed consent of the participants in the study
Disrupted liver enzymes (AST and ALT greater than 60).
Total cholesterol above 200
Total bilirubin equal to or greater than 2
GGT more than 60
Exclusion Criteria
With other blood diseases and liver diseases such as HBV, HCV and HIV
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method iver Enzymes. Timepoint: Before treatment, with a month's interval in six month from starting treatment. Method of measurement: Blood tests.
- Secondary Outcome Measures
Name Time Method